Next Generation Sequencing-Based Tumor Genomic Profiling Aids in Detecting Hereditary Variants in Cancer Risk Genes
CHICAGO (May 20, 2015) — Cancer patients are increasingly having their tumors tested using comprehensive genomic profiling (CGP) to identify genetic mutations that can be targeted by precision therapies. A new study from investigators at Fox Chase Cancer Center in collaboration with Foundation Medicine has shown that 3-7% of patients receiving CGP could have a genetic mutation that they inherited from a parent that can also be identified using results from next generation sequencing (NGS)-based CGP.